CMP Pharma announces calcium channel blocker ‘Norliqva’ availability

Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.

Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS

Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022

Ovensa and Celanese to collaborate to advance precision drug delivery

Vial to launch oncology CRO, Arati Rao named as First Advisor

The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.

BGS Gleneagles launches its refurbished advanced emergency & trauma center

120+ members of multi-disciplinary medical team are trained to provide seamless, outcome driven trauma and emergency care

FDA approves Roche’s Evrysdi for use in babies under two months with SMA

Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date

Ayu Health Hospitals announces t expansion plan in Rajasthan

This expansion announcement came right after raising series B funding of $27 Mn in a round led by Fundamentum Partnership, earlier this month.

USFDA accepts dupilumab for priority review in adults with prurigo nodularis

Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved

US FDA accepts new drug application filed by Avillion for AstraZeneca's PT027

Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study

LintonPharm to release data on Catumaxomab at ASCO meeting

The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis